Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Jun 27, 2026; 18(6): 118659
Published online Jun 27, 2026. doi: 10.4240/wjgs.118659
Published online Jun 27, 2026. doi: 10.4240/wjgs.118659
Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics
Jin-Ping Li, Nursing Department of Medical College, Yangzhou Polytechnic University, Yangzhou 225009, Jiangsu Province, China
Lei Wang, Department of Endocrinology, Nanjing Lishui District People’s Hospital, Nanjing 211200, Jiangsu Province, China
Li Dong, Department of Endocrinology, Nanjing Red Cross Hospital, Nanjing 210001, Jiangsu Province, China
Chun Bai, Department of Breast Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi 435002, Hubei Province, China
Co-first authors: Jin-Ping Li and Lei Wang.
Author contributions: Li JP and Wang L participated in the research design and data collection, conducted data analysis and paper writing as co-first authors; Dong L was responsible for research and design, funding application, and data analysis; Bai C is responsible for reviewing and editing, communication and coordination, ethical review, copyright and licensing, and follow-up; all authors have read and approved the final manuscript.
AI contribution statement: We didn't use AI to write this manuscript. We used DeepL to assist in polishing the language of the manuscript. All text is human-written.
Institutional review board statement: The research was reviewed and approved by Nanjing Red Cross Hospital.
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Data sharing statement: No other data available.
Corresponding author: Chun Bai, Chief Physician, Department of Breast Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, No. 141 Tianjin Road, Huangshigang District, Huangshi 435002, Hubei Province, China.
Received: January 23, 2026
Revised: February 6, 2026
Accepted: April 10, 2026
Published online: June 27, 2026
Processing time: 142 Days and 19.1 Hours
Revised: February 6, 2026
Accepted: April 10, 2026
Published online: June 27, 2026
Processing time: 142 Days and 19.1 Hours
Core Tip
Core Tip: This retrospective cohort study in Chinese patients with obesity and type 2 diabetes mellitus found that adding semaglutide after sleeve gastrectomy, compared to surgery alone, significantly improved short-term diabetes remission and metabolic indicators (glucose, lipids, weight, islet function) without extra safety risks. The results demonstrate synergy between surgery and glucagon-like peptide-1 receptor agonist therapy, supporting an integrated “surgery plus postoperative drug intensification” model to address suboptimal or declining long-term outcomes. This offers an evidence-based treatment intensification option for optimizing management in clinical practice.